MHB018A is a novel, subcutaneously administered antibody targeting insulin-like growth factor 1 receptor (IGF-1R) for the treatment of thyroid eye disease (TED) ... It is designed to inhibit IGF-1R ...
Linsitinib is an investigational, oral, small-molecule inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and is currently being evaluated in the pivotal Phase 3 ORBIT trial in adults with moderate to severe active TED.
Proceeds from the financing will support the continued clinical advancement of linsitinib, an oral small molecule inhibitor of IGF-1R (insulin-like growth factor 1 receptor), a validated target for the treatment of TED.